Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD - Frederiksen, M T; Ainsworth, M A; Brynskov, J (Inflamm Bowel Dis, 2014)
et al.